PharmaShots | Incisive News in 3 Shots

Subscribe Now

Ractigen Therapeutics

Ractigen Therapeutics Reports the First Patient Dosing with RAG-17 in P-I Study to Treat Amyotrophic Lateral Sclerosis (ALS)

Ractigen Therapeutics Reports the First Patient Dosing with RAG-17 in P-I Study to Treat Amyotrophic Lateral Sclerosis (ALS)

December 25, 2024

Ractigen Therapeutics’ RAG-18 Gains the US FDA’s Orphan Drug Designation to Treat DMD and BMD

Ractigen Therapeutics’ RAG-18 Gains the US FDA’s Orphan Drug Designation to Treat DMD and BMD

August 23, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us